


# Hsa-miR-21-5p miRNA Probe (DIG)

Catalog # MI0002      Size 100 uL

## Applications



### Chromogenic *In Situ* Hybridization (FFPE Tissue)

(A) microRNA in situ hybridization analysis of Hsa-miR-21-5p miRNA Probe (DIG) showing positive staining on FFPE human testis, liver and breast cancer tissues.

(B) microRNA in situ hybridization analysis of Hsa-miR-21-5p miRNA Probe (DIG) showing negative staining on FFPE human pancreas tissue and the negative controls on FFPE testis, liver and breast cancer tissues in the absence of probe (No Probe) followed by incubation with primary antibody, secondary antibody and detection reagents.

## Specification

<b>Product Description</b>	Hsa-miR-21-5p miRNA Probe (DIG) designed from mature human miR-21 sequence.
<b>miRbase ID</b>	MIMAT0000076
<b>Origin</b>	Human
<b>Reactivity</b>	Human
<b>Form</b>	Liquid
<b>Conjugation</b>	Digoxigenin (DIG)
<b>Notice</b>	Use of FFPE miRNA ISH Pretreatment Solution for the pretreatment of formalin-fixed paraffin-embedded (FFPE) tissue sections is strongly recommended.
<b>Regulation Status</b>	For research use only (RUO)
<b>Supplied Product</b>	10 reactions, 100 uL miRNA probe
<b>Storage Instruction</b>	Store at 4°C.

## Applications

- Chromogenic *In Situ* Hybridization (FFPE Tissue)

(A) microRNA in situ hybridization analysis of Hsa-miR-21-5p miRNA Probe (DIG) showing positive staining on FFPE human testis, liver and breast cancer tissues.

(B) microRNA in situ hybridization analysis of Hsa-miR-21-5p miRNA Probe (DIG) showing negative staining on FFPE human pancreas tissue and the negative controls on FFPE testis, liver and breast cancer tissues in the absence of probe (No Probe) followed by incubation with primary antibody, secondary antibody and detection reagents.